Overview

RealTime Software Solutions received a strategic investment from LLR Partners to accelerate growth and product innovation.

Significance

The market for clinical trial support services for pharmaceutical sponsors and CROs has reached an estimated $15 billion globally, with approximately 400,000 studies conducted each year. The complexity of these clinical trials has also increased significantly in recent years as more studies utilize decentralized and hybrid models, fueled by the growth in precision and specialized medicines and trial disruptions caused by the global pandemic. As a result, sponsors and CROs are demanding new solutions to maximize efficiencies, improve trial management, and reduce costs.

With a focus on solving problems and providing systems that make the clinical research process more efficient and compliant, RealTime Software Solutions (RealTime) provides innovative software products for clinical trial research sites, site networks, sponsors, and CROs to manage complex clinical research processes with powerful, user-friendly interfaces that are revolutionizing how research gets done. The company’s leadership position in the clinical research technology market made it the perfect investment opportunity for LLR Partners (LLR), a firm with a long history of investing and supporting the growth of pharma services and technology businesses.

Crosstree’s Role

Crosstree acted as exclusive financial advisor to RealTime in its recapitalization by LLR Partners through:

• Leveraging market expertise to develop a compelling presentation of RealTime’s value proposition to potential investors
• Evaluating a broad slate of potential strategic and financial partners to find the ideal fit
• Efficiently executing the due diligence and metrics reporting processes for a timely closing